News | Prostate Cancer | August 16, 2016

European observational study finds improved mortality at hospitals with highest percentage of radiotherapy and/or prostatectomy

high-risk prostate cancer, radical local treatment, Umea University Sweden study, mortality

August 16, 2016 — High-risk prostate cancer patients treated at hospitals with a high proportion of administered radical local treatment (radiotherapy or prostatectomy) only have half of the mortality risk of men treated at hospitals with the lowest proportion. This is according to a new study conducted by researchers at Umeå University in Sweden and published in European Urology.

"The results suggest that the combination of thorough examination and subsequent radical local therapy can prolong life for men with very high-risk prostate cancer," said Pär Stattin, a researcher at the Department of Surgical and Perioperative Sciences, who led the study.

Using patient data from the National Prostate Cancer Register (NPCR) of Sweden, the researchers investigated the link between prostatectomy or full-dose radiotherapy and mortality in men with deadly high-risk prostate cancer. Differences in treatment selection were analyzed on a group basis, whereas mortality from prostate cancer and other causes was analyzed on an individual basis.

Results show that men with a very high-risk prostate cancer, who were treated at hospitals with the highest proportion of radical treatment, were only half as likely (mortality rate ratio; MRR 0.51) to die from prostate cancer compared to men treated at hospitals where radical local therapy was administered the least. However, since this was an observational study, the potential effects of high-intensity in diagnostic activity and work-up cannot be isolated from therapeutic activity.

"Our data suggests that there are benefits of radical local therapy for men with very advanced forms of prostate cancer. However, these men most often only receive hormonal treatment. To confirm our findings and hopefully to improve treatment praxis, there is a need for a randomized study of the effects of local radical therapy on patients with very high-risk prostate cancer," said Stattin.

For more information: www.europeanurology.com


Related Content

News | Radiation Oncology

May 2, 2025 — GE HealthCare has announced an intended expansion of its radiation oncology portfolio as well as the ...

Time May 03, 2025
arrow
News | Radiology Education

April 21, 2025 — On June 20, the American Society of Radiologic Technologists (ASRT) will award Life Member status to ...

Time April 21, 2025
arrow
News | Radiology Business

April 16, 2025 — According to a new report, the U.S. Radiotherapy Market is projected to reach $2.49 billion by 2030 ...

Time April 17, 2025
arrow
News | ASTRO

March 14, 2025 — Another pivotal milestone in the nation’s fight against cancer recently took place with the ...

Time March 17, 2025
arrow
News | Computed Tomography (CT)

Royal Philips recently received 510(k) clearance from the US Food and Drug Administration (FDA) for its detector-based ...

Time November 13, 2024
arrow
News

Aug. 5, 2024 — Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that adding ...

Time August 09, 2024
arrow
News | PET-CT

July 31, 2024 — In a head-to-head comparison with FDG PET/CT, FDG PET/MRI demonstrated comparable or superior diagnostic ...

Time July 31, 2024
arrow
Feature | Radiation Oncology | By Christine Book

News emerging from several leading organizations and vendors in the radiation therapy arena came in at a fast pace in ...

Time July 30, 2024
arrow
News | Radiology Business

July 25, 2024 — Immunis, Inc., a clinical-stage biotech developing groundbreaking secretome therapeutics for age and ...

Time July 25, 2024
arrow
News | Radiopharmaceuticals and Tracers

July 24, 2024 — Telix Pharmaceuticals Limited announced that the United States (U.S.) Food and Drug Administration (FDA) ...

Time July 24, 2024
arrow
Subscribe Now